Approved accessible "loncastuximab tesirine-lpyl for injection"

Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma and high-grade B-cell lymphoma. Loncastuximab tesirine, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19. Loncastuximab tesirine was approved for medical use in the United States in April 2021, and in the European Union in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

The most common side effects include increased levels of gamma-glutamyltransferase (GGT, a liver enzyme), neutropenia (low levels of neutrophils, a type of white blood cell), tiredness, anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), nausea (feeling sick), peripheral edema (swelling due to fluid retention, especially of the ankles and feet) and rash.

How can 1 go about obtaining loncastuximab tesirine-lpyl for injection?

If loncastuximab tesirine-lpyl for injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

Zynlonta (loncastuximab tesirine-lpyl for injection) for intravenous use Initial U.S. Approval: 2021